Tarcocimab tedromer - Kodiak Sciences
Alternative Names: KSI-301; ZenkudaLatest Information Update: 15 Apr 2026
At a glance
- Originator Oligasis
- Developer Kodiak Sciences
- Class Antibodies; Biopolymers; Drug conjugates; Eye disorder therapies; Immunoconjugates
- Mechanism of Action Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Diabetic macular oedema; Diabetic retinopathy; Retinal vein occlusion; Wet age-related macular degeneration
Most Recent Events
- 31 Mar 2026 Efficacy data from the phase III GLOW2 trial in Diabetic retinopathy released by Kodiak Sciences
- 27 Mar 2026 Kodiak Sciences announces intention to submit BLA for Diabetic retinopathy
- 27 Mar 2026 Efficacy and adverse events data from a phase III GLOW2 trial in Diabetic retinopathy released by Kodiak Sciences